First identification of epitopes which shape CD8 T cell response to commercial live attenuated vaccine has implications across RNA virus vaccine development Vaccine primes immune system against T cell epitopes that would be minor or subdominant in a natural infection and are derived from internal proteins Abingdon, UK and Rio de Janeiro, Brazil, 19 August […]
This author has not written his bio yet.
But we are proud to say that gatekeeper contributed 31 entries already.
Entries by gatekeeper
Emergex Vaccines and George Mason University’s (Mason) National Center for Biodefense and Infectious Diseases (NCBID) enter into an agreement relating to the development of CD8+ priming RNA virus vaccines In particular, NCBID researchers will partner to provide additional expertise, resources, and vital samples to complement Emergex’s existing vaccine programs, including for SARS-CoV-2 Abingdon, UK, 22 […]
Emergex publishes three White Papers highlighting the case for developing set-point vaccines to create a universal coronavirus vaccine
Emergex develops set-point vaccines to prevent some of the world’s most immediate and virulent diseases such as Zika, Dengue Fever, Ebola and pandemic Flu Vickers Venture Partners led the fundraising and Dr Finian Tan, Chairman of Vickers Venture Partners joins Emergex’s Board of Directors Capital supports pipeline developments, including progressing its first-in-man Flavivirus (Dengue) vaccine […]
Emergex today announced it has successfully completed the first step in the development of a candidate vaccine for the Gram-negative intracellular coccobacillus, Francisella tularensis.
Emergex today announced the successful completion of preclinical testing of its lead vaccine candidate for Dengue Fever.
Emergex today announced that it has signed an R&D agreement with the Institute of Molecular and Cell Biology (IMCB) in Singapore to develop a fully synthetic vaccine against human viruses that cause Hand, Foot and Mouth Disease (HFMD). Emergex and IMCB will collaborate closely to develop the new vaccine, combining their personnel, specialist knowledge and expertise.
Emergex today announces the appointment of Athanasios Papadopoulos, MD, as Chief Medical Officer (CMO), effective 1st March 2019. Dr. Papadopoulos will report directly to Emergex’s CEO Professor Thomas Rademacher.
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a novel approach to the development of vaccines for infectious diseases, today announces that it has successfully secured a state-of-the-art-research and development (R&D) facility at Milton Park, Oxfordshire.
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the successful completion of preclinical toxicology testing on the gold nanoparticle carrier system that forms the fundamental basis for Emergex’s entire infectious disease vaccine platform.
© EMERGEX VACCINES
Website maintained by Digital Trading